AACR 2021: A novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model reveals enhanced efficacy of combined TIGIT and PD-L1 blockade against cancer

Author: Chonghui Liu, Xiaofei Zhou, Yanan Guo, Eugene Lin, Yuelei Shen

Competitive binding of TIGIT to CD155 and CD112 prevents signaling through CD226, which is an NK activating receptor that contributes to anti-tumor responses.
Biocytogen established a novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model to preclinically evaluate in vivo efficacy of combined human TIGIT and PD-1/PD-L1 blocking agents.
Anti-human PD-L1 and anti-human TIGIT antibodies synergize to inhibit tumor growth of MC38-hPD-L1 cells in B-hPD-1/hPD-L1/hTIGIT mice.
B-hPD-1/hPD-L1/hTIGIT mice are a useful tool for investigating the in vivo efficacy of TIGIT therapeutic candidates alone, or in combination with PD-1/PD-L1 antibodies.

Please fill out the form below to request a download of this poster

First Name *

Last Name *

Company/ Institution*

Work Email *

Country *

State/ Province *

How did you hear about us? *